Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Launching in 2022, its availability will be expanded to the global market
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The interim data combines three mRNAs into one therapy injected directly into the tumour
Subscribe To Our Newsletter & Stay Updated
